Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors
Author:
Affiliation:
1. Proteros Biostructures GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried, Germany
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/jm301658d
Reference35 articles.
1. The Raf/MEK/ERK pathway: new concepts of activation
2. The RAF proteins take centre stage
3. Mutations of the BRAF gene in human cancer
4. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
5. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators via AhR Antagonism for the Treatment of Duchenne Muscular Dystrophy;Journal of Medicinal Chemistry;2024-05-21
2. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors;Bioorganic Chemistry;2023-11
3. Applications of palladium-catalyzed C–N cross-coupling reactions in pharmaceutical compounds;RSC Advances;2023
4. BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy;Pharmacological Research;2022-08
5. Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer;European Journal of Medicinal Chemistry;2020-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3